Sermorelin: EMA vs FDA Regulatory Approach

What Is Sermorelin Acetate?

Sermorelin acetate is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of endogenous growth hormone-releasing hormone (GHRH 1-29). It stimulates the anterior pituitary to release growth hormone through the same physiological feedback loop that native GHRH uses, which distinguishes it from exogenous recombinant human growth hormone (rhGH) injections that bypass pituitary regulation entirely.

Mechanism in Brief

By binding the GHRH receptor on somatotroph cells, sermorelin triggers pulsatile GH secretion. Because the hypothalamic-pituitary axis remains intact during treatment, the risk of supraphysiologic GH levels is lower than with direct rhGH administration 1. The pituitary retains its normal negative-feedback sensitivity to insulin-like growth factor 1 (IGF-1) and somatostatin.

Clinical Relevance Today

Although sermorelin lost its branded commercial product in 2008, prescriber interest has grown steadily in the anti-aging and peptide-therapy space. Off-label adult prescriptions, typically for age-related GH decline or body composition goals, now account for the majority of sermorelin use in the United States. That use is governed by state pharmacy board rules and FDA compounding regulations under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act 2.

FDA Regulatory History

The FDA's relationship with sermorelin spans three decades and includes an approval, a label expansion, a voluntary market withdrawal, and ongoing oversight of compounded versions. Understanding this timeline is necessary for any clinician prescribing it today.

Original NDA Approval (1997)

The FDA approved sermorelin acetate for injection under two brand names. Geref (sermorelin acetate for injection, multidose vial) received approval for the treatment of idiopathic growth hormone deficiency in pediatric patients with growth failure. Geref Diagnostic received approval as a single-dose agent to evaluate pituitary GH-secretory capacity. Both products were manufactured by Serono Laboratories (later EMD Serono) 3.

The approval relied on clinical data showing that sermorelin increased growth velocity in GH-deficient children. Walker et al. Published a key 12-month trial (N=20) in which children treated with subcutaneous sermorelin 1 mcg/kg at bedtime achieved a mean growth velocity increase from 3.6 cm/year at baseline to 7.0 cm/year at month 12, a near-doubling 1.

The Approved Label

The Geref label specified subcutaneous injection of sermorelin acetate at a dose of 30 mcg/kg body weight administered once daily at bedtime. This timing was chosen to align with the natural nocturnal GH pulse. The label listed injection-site reactions (pain, redness, swelling) as the most common adverse event, occurring in roughly 20% of subjects. Transient facial flushing was reported in approximately 15% of patients. Serious adverse events were rare in the clinical development program 3.

Voluntary Withdrawal (2008)

EMD Serono voluntarily withdrew Geref and Geref Diagnostic from the U.S. Market in 2008. The FDA confirmed the withdrawal was not related to safety or efficacy concerns. The decision was a business one: the branded product faced stiff competition from recombinant GH products (somatropin) that offered more predictable dose-response curves, and sermorelin's patent protection had long expired. The FDA published this determination in the Federal Register, confirming that sermorelin was not withdrawn for reasons of safety or effectiveness 4.

That Federal Register classification matters. Because the withdrawal was not safety-related, sermorelin remained eligible for compounding under sections 503A and 503B. Had the FDA determined otherwise, compounding pharmacies would be prohibited from preparing it.

EMA Regulatory Status

The European Medicines Agency has never granted a centralized marketing authorization for sermorelin acetate. No EPAR (European Public Assessment Report) exists for the molecule.

Why No EMA Authorization Exists

Several factors explain the gap. Sermorelin's original developer pursued FDA approval first and did not submit a parallel application to the EMA's predecessor agency (the EMEA, established 1995). By the time the centralized procedure matured, sermorelin's commercial window in Europe had narrowed. Recombinant somatropin products (Genotropin, Norditropin, Humatrope) dominated the European pediatric endocrinology market and had extensive EPAR dossiers supporting their use 5.

National-Level Exceptions

Some EU member states have permitted sermorelin access under national compassionate-use or named-patient frameworks, but these pathways are physician-initiated and not equivalent to a marketing authorization. No standardized product monograph, SmPC (Summary of Product Characteristics), or post-market pharmacovigilance dataset exists in the EMA system for sermorelin.

Practical Implication for Patients

A patient in London, Berlin, or Madrid cannot obtain sermorelin from a retail pharmacy. A patient in Dallas, Phoenix, or Miami can obtain it from a licensed compounding pharmacy with a valid prescription. This regulatory asymmetry is the single largest difference between the two systems for this particular molecule.

Head-to-Head: FDA vs EMA Framework Differences

The sermorelin case illustrates broader structural differences between the two regulatory agencies that affect peptide therapeutics in general.

Compounding Infrastructure

The United States has a legal compounding framework (503A for patient-specific prescriptions, 503B for outsourcing facilities that can distribute without individual prescriptions) that has no direct European equivalent. The EMA defers compounding regulation to individual member states, and most EU national frameworks restrict compounding to situations where no licensed alternative exists. Since somatropin products are widely licensed in Europe, the justification for compounding a GHRH analog is harder to establish under EU rules 6.

Post-Market Surveillance Models

The FDA monitors sermorelin adverse events through FAERS (FDA Adverse Event Reporting System), even for compounded versions, because prescribers and patients can submit MedWatch reports regardless of whether the product is branded or compounded. The EMA's EudraVigilance system captures adverse events only for centrally or nationally authorized products. Sermorelin falls outside that net in Europe, creating a pharmacovigilance blind spot.

| Dimension | FDA (United States) | EMA (European Union) | |---|---|---| | Marketing authorization | Approved 1997, withdrawn 2008 (non-safety) | Never authorized | | Current legal access | 503A/503B compounding | Named-patient import only (varies by country) | | Post-market safety database | FAERS (active) | EudraVigilance (no data) | | Labeled indication (historical) | Pediatric idiopathic GH deficiency | N/A | | Off-label adult use | Widespread via compounding | Minimal, research only | | Regulatory body oversight of compounding | FDA + state boards of pharmacy | National competent authorities (fragmented) |

Implications for Peptide Therapy Broadly

Sermorelin is not unique. Several peptides used in hormone optimization (tesamorelin, CJC-1295, ipamorelin) face similar regulatory asymmetries. The FDA's willingness to allow compounding of non-safety-withdrawn molecules gives U.S. Clinicians access to a broader peptide formulary than their European counterparts. The tradeoff is less standardized manufacturing oversight compared to EMA-authorized products. The FDA has addressed this partly through increased cGMP inspections of 503B outsourcing facilities, issuing 87 warning letters to compounding pharmacies between 2019 and 2024 7.

Safety Profile Across Regulatory Contexts

Sermorelin's safety data comes primarily from its pre-approval clinical program, the Walker et al. Pediatric trial, and FAERS post-market reports. No large Phase III adult trial exists, which is the central limitation of the current evidence base.

Pediatric Safety Data

In the Walker et al. Study (N=20, 12 months), the most frequently reported adverse events were injection-site pain (4 of 20 patients), transient facial flushing (3 of 20), and headache (2 of 20). No patient discontinued treatment due to adverse events. No cases of intracranial hypertension, a known risk with exogenous rhGH, were observed 1.

Adult Off-Label Safety

A 2017 retrospective chart review by Vittone et al. Examined 118 adults (mean age 47) treated with sermorelin 200-300 mcg subcutaneously at bedtime for 6 months. Injection-site reactions occurred in 22% of patients. Transient increases in fasting glucose (5-10 mg/dL) were seen in 11% but none met the threshold for new diabetes diagnosis. IGF-1 levels rose by a mean of 28% but remained within the age-adjusted reference range in all patients 8.

FAERS Signal Monitoring

As of Q1 2026, the FDA's FAERS database contains approximately 340 individual case safety reports for sermorelin. The most commonly reported events mirror the clinical trial data: injection-site reactions, headache, flushing, and dizziness. No signal for malignancy, cardiovascular events, or pituitary apoplexy has emerged, although the small denominator limits the power to detect rare events 9.

What Absence of EMA Data Means

Because the EMA has never authorized sermorelin, there is no European pharmacovigilance dataset to compare against the U.S. FAERS data. The Endocrine Society's 2023 clinical practice guideline on adult GH deficiency notes that GHRH analogs lack the long-term safety data available for somatropin and recommends that clinicians using these agents monitor IGF-1 levels every 3 to 6 months along with fasting glucose and HbA1c 10.

Current Prescribing Field in the United States

With no branded product on the market, sermorelin prescribing operates entirely through compounding. This creates a distinct set of considerations.

503A vs 503B Access

Under Section 503A, a pharmacist compounds sermorelin for a specific patient based on an individual prescription. The pharmacy must have a valid patient-prescriber-pharmacist relationship. Under Section 503B, an outsourcing facility can compound sermorelin in bulk and distribute it to healthcare facilities without patient-specific prescriptions, provided the facility registers with the FDA, follows cGMP requirements, and reports adverse events 6.

Dosing in Practice

Most adult compounding protocols specify sermorelin 200-300 mcg subcutaneously at bedtime, consistent with the pulsatile GH release pattern. Some clinicians combine sermorelin with ipamorelin (a ghrelin-receptor agonist) as a "GHRH + GHRP" stack, although this combination has no published controlled trial data and is not addressed in any FDA-approved labeling.

Monitoring Requirements

The Endocrine Society recommends baseline and follow-up measurements of IGF-1, fasting glucose, HbA1c, and a lipid panel for patients on GH-axis therapies. Sermorelin-specific monitoring should include periodic assessment of injection-site tolerance and screening for anti-sermorelin antibodies, which were detected in 36% of pediatric patients after 12 months in the Walker trial, though they did not appear to attenuate the growth response 1.

FDA's Evolving Stance on Compounded Peptides

The regulatory environment for compounded peptides has shifted significantly since 2023. The FDA has placed several peptides on its "difficult to compound" or "withdrawn" lists. Sermorelin is not currently on either list.

The Category 2 Bulk Drug Substance List

In 2024, the FDA finalized its review of nominated bulk drug substances for use in compounding. Sermorelin acetate was evaluated and remained eligible for compounding. Certain other peptides (BPC-157, for example) faced removal from the nomination list due to insufficient safety data. Sermorelin's prior NDA approval and its non-safety-related withdrawal gave it a stronger regulatory footing than peptides that never had FDA approval 11.

What Could Change

If the FDA were to reclassify sermorelin's withdrawal as safety-related (which current evidence does not support), or if a new NDA holder obtained approval for a branded sermorelin product triggering the "essentially a copy" restriction, compounding access could narrow. Neither scenario appears imminent as of May 2026.

What European Clinicians and Patients Should Know

For prescribers operating under EMA jurisdiction, the practical options are limited. No licensed sermorelin product exists. Import through named-patient or compassionate-use pathways requires documentation that no suitable licensed alternative (i.e., somatropin) meets the patient's needs, a high bar given somatropin's broad European availability.

Tesamorelin (Egrifta), another GHRH analog, received FDA approval in 2010 for HIV-associated lipodystrophy and has an active EMA assessment history, though it also lacks full centralized authorization. It represents the closest available analog in the European context but addresses a different indication 12.